Trovagene's proprietary KRAS assay enables physicians to determine mutational
status, monitor treatment response, and use genomics to aid in predicting patient prognosis
Development and application of an oligonucleotide microarray for mutational
status ranks among one of the most important scientific advances in colorectal cancer and has the potential to redefine how these patients are currently treated.
As such, this semiautomated method, coupled with the low costs of analysis per sample, would be suitable for rapid, large-scale mutational
screening of frequent and rare mutations.
There's growing interest in our molecular diagnostic tests by hematology-oncology specialists, particularly for the cell-free detection and monitoring of mutational
status in patients with histiocytic diseases, as well as other hematologic malignancies that harbor the BRAF V600E mutation," said Mark Erlander, Ph.
In some cases, to test the effect of different variables on mutational
analysis by SSCP, we selected samples known to harbor single nucleotide changes in the human insulin receptor (HIR) gene, in the adenomatous polyposis coli (APC) gene, and in the mismatch repair gene hMLH1 (11-13).
Prospective blinded study demonstrates ability to accurately determine mutational
status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA
The hERG channel: biology and mutational
BRAF V600E assay improves determination of mutational
status and allows monitoring of treatment response
The full details of the structure are described in "Structure of a receptor-binding fragment of reelin and mutational
analysis reveal a recognition mechanism similar to endocytic receptors" in the June 12, 2007 issue of Proceedings of the National Acadamy of Sciences (PNAS).
Secondary objectives include correlating quantitative EGFR mutational
load over time with tumor burden, and demonstrating detection of the resistant EGFR T790M mutation prior to clinical or radiographic progression in lung cancer patients treated with tyrosine kinase inhibitor therapy.
Today, genetic mutational
tests (BRCA 1 and 2 genes) can detect genetic disposition of breast cancer risk, but aggressive screening, usually with breast MRI, is chosen more often than preventive mastectomy by patients who test BRCA-positive," he said.